Vernon E Steele

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Development of cancer chemopreventive drugs based on mechanistic approaches
    Vernon E Steele
    National Cancer Institute, EPN 2108, MSC 7322, 9000 Rockville Pike, National Institutes of Health, Bethesda, MD 20892 7322, USA
    Mutat Res 591:16-23. 2005
  2. ncbi Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
    Int J Cancer 123:2254-9. 2008
  3. ncbi Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays
    V E Steele
    Chemoprevention Branch, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Carcinogenesis 21:63-7. 2000
  4. ncbi Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer
    Vernon E Steele
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 7322, USA
    Mutat Res 523:137-44. 2003
  5. ncbi Current mechanistic approaches to the chemoprevention of cancer
    Vernon E Steele
    Chemoprevention Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Biochem Mol Biol 36:78-81. 2003
  6. ncbi Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers
    Vernon E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, NIH, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 2:951-6. 2009
  7. ncbi Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20852, USA
    J Urol 183:1598-603. 2010
  8. ncbi Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis
    Ronald A Lubet
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 2:161-7. 2009
  9. ncbi Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 5:1073-8. 2006
  10. ncbi Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20852, USA
    Oncol Rep 27:1400-6. 2012

Collaborators

Detail Information

Publications65

  1. ncbi Development of cancer chemopreventive drugs based on mechanistic approaches
    Vernon E Steele
    National Cancer Institute, EPN 2108, MSC 7322, 9000 Rockville Pike, National Institutes of Health, Bethesda, MD 20892 7322, USA
    Mutat Res 591:16-23. 2005
    ..Each cancer type, organ location, or individual genetic background may require a custom combination of prevention strategies to be successful...
  2. ncbi Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
    Int J Cancer 123:2254-9. 2008
    ..In summary, rosiglitazone over a wide dose range enhanced urinary bladder carcinogenesis in the OH-BBN model in rats...
  3. ncbi Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays
    V E Steele
    Chemoprevention Branch, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Carcinogenesis 21:63-7. 2000
    ..Such anticancer mechanisms may well be responsible for the cancer preventive efficacies seen in both experimental and human studies...
  4. ncbi Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer
    Vernon E Steele
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 7322, USA
    Mutat Res 523:137-44. 2003
    ..As newer more specific drugs are developed with few adverse effects this important prevention strategy may become a reality...
  5. ncbi Current mechanistic approaches to the chemoprevention of cancer
    Vernon E Steele
    Chemoprevention Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Biochem Mol Biol 36:78-81. 2003
    ..Thus, agent combination prevention strategies are essential to decrease cancer morbidity. Furthermore, each cancer type may require custom combination of prevention strategies to be successful...
  6. ncbi Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers
    Vernon E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, NIH, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 2:951-6. 2009
    ..These data show that both naproxen and NO-naproxen are effective agents against urinary bladder and colon, but not mammary, carcinogenesis...
  7. ncbi Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20852, USA
    J Urol 183:1598-603. 2010
    ..We optimized agent testing in an in vivo bladder cancer model and determined the most sensitive, relevant protocol to test efficacy in clinical prevention trials...
  8. ncbi Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis
    Ronald A Lubet
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 2:161-7. 2009
    ..Similarly, atorvastatin failed to alter the development of estrogen receptor-negative mammary carcinomas in a new animal model using bitransgenic mice (MMTV-Neu(+/-)/p53KO(+/-)), whereas bexarotene (250 mg/kg diet) was effective...
  9. ncbi Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 5:1073-8. 2006
    ..Thus, R115777 was active in the prevention and therapy of these chemically induced mammary cancers, but was strikingly more effective in cancers with HaRas mutations...
  10. ncbi Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20852, USA
    Oncol Rep 27:1400-6. 2012
    ..There was minimal overlap of efficacy. That is, models which were relatively susceptible to NSAIDs or COX-2 inhibitors tended not to be sensitive to Targretin and vice versa...
  11. ncbi Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Blvd, Bethesda, MD 20852, USA
    Oncol Rep 25:1389-97. 2011
    ..In particular, cell cycle genes related to the anaphase protein complex (APC) pathway, including CDC 20, cyclin B1, BUB1 and both of the Aurora kinases, were significantly decreased...
  12. ncbi Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 6:2022-8. 2007
    ..The bioavailability of these tea polyphenols to different organ sites may contribute to the differing preventive efficacy of Polyphenon E against urinary bladder and mammary cancers...
  13. ncbi Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 7:972-9. 2008
    ..Finally, combining suboptimal doses of Iressa with suboptimal doses of vorozole (an aromatase inhibitor) or targretin (a retinoid X receptor agonist) yielded greater chemopreventive efficacy than any of these agents given alone...
  14. ncbi Effects of 5,6-benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: is DIM a substitute for I3C?
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, NIH, NCI, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Oncol Rep 26:731-6. 2011
    ..In contrast, DIM had minimal effects in either model; arguing that administration of DIM is not analogous to administration of I3C...
  15. ncbi The use of animal models for cancer chemoprevention drug development
    Vernon E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA
    Semin Oncol 37:327-38. 2010
    ..Whether validated or not, animal efficacy data remain central to the clinical trial decision-making process...
  16. ncbi Targeting the AKT protein kinase for cancer chemoprevention
    James A Crowell
    Division of Cancer Prevention, National Cancer Institute, NIH, Executive Plaza North, Room 2117, 900 Rockville Pike, Bethesda, MD 20892, USA
    Mol Cancer Ther 6:2139-48. 2007
    ....
  17. ncbi Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Carcinogenesis 26:441-8. 2005
    ..Determination of serum IGF1 levels showed that treatment of rats with highly effective doses of Targretin at 272 mg/kg diet or at 60 or 20 mg/kg body wt/day by gavage caused significantly decreased serum IGF1 levels...
  18. ncbi 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Carcinogenesis 26:571-8. 2005
    ..The anti-apoptotic protein survivin was not expressed in normal bladder epithelium, but was variably expressed in cancers. FHIT and survivin expressions were similar in cancers from indomethacin-treated and non-treated mice...
  19. ncbi Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells
    Vernon E Steele
    Endocrine Section, Laboratory of Clinical Investigation, Division of Intramural Research, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD 20892, USA
    Anticancer Res 26:3205-15. 2006
    ..Because DHEA can be converted to androgens or estrogens, such use may promote prostate cancer. In this study, the effects of DHEA were compared with those of DHT using gene expression array profiles in human LNCaP prostate cancer cells...
  20. ncbi Correlation between electron-donating ability of a series of 3-nitroflavones and their efficacy to inhibit the onset and progression of aberrant crypt foci in the rat colon
    Vernon E Steele
    Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892 7322, USA
    Cancer Res 62:6506-9. 2002
    ..The above correlations may be of predictive value in the search for new chemoprotective agents. The overall molecular mechanism of the inhibition of ACF by the 3-nitroflavones under study appears to involve redox reactions...
  21. ncbi Is inducible nitric oxide synthase a target for chemoprevention?
    James A Crowell
    National Cancer Institute, Division of Cancer Prevention, Chemopreventive Agent Development Research Group, Bethesda, Maryland 20892, USA
    Mol Cancer Ther 2:815-23. 2003
    ....
  22. ncbi Null effect of dietary restriction on prostate carcinogenesis in the Wistar-Unilever rat
    David L McCormick
    Life Sciences Group, IIT Research Institute, Chicago, IL 60616, USA
    Nutr Cancer 57:194-200. 2007
    ..Reducing mean body weight by up to 25% through chronic dietary restriction has no effect on the induction of prostate cancers in the Wistar-Unilever rat model...
  23. ncbi Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT)
    Fadel S Alyaqoub
    Medical University of Ohio, Toledo OH 43614, USA
    Carcinogenesis 27:2442-7. 2006
    ..These results support the combined use of budesonide and R115777 in prevention of lung tumors and suggest that reversal of DNA hypomethylation in lung tumors would be useful as a surrogate endpoint biomarker for prevention...
  24. ncbi Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets
    Chinthalapally V Rao
    Department of Medicine, Hem Onc Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    Mol Cancer Ther 5:1530-8. 2006
    ..These results pave the way for the rational design of human clinical trials...
  25. ncbi Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas
    Stephan Woditschka
    McArdle Laboratory for Cancer Research, University of Wisconsin, 1400 University Avenue, Madison, WI 53706, USA
    Cancer Res 66:6884-91. 2006
    ..The model is useful for assessing the efficacy of chemopreventive agents, specifically those compounds that target hormonally nonresponsive tumors...
  26. ncbi Chemoprevention of colon carcinogenesis by oleanolic acid and its analog in male F344 rats and modulation of COX-2 and apoptosis in human colon HT-29 cancer cells
    Naveena B Janakiram
    Department of Medicine, Hem Onc Section, OU Cancer Institute, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Pharm Res 25:2151-7. 2008
    ..7 macrophage cell lines...
  27. ncbi Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (Zarnestra MT)
    Fadel S Alyaqoub
    Medical University of Ohio, Toledo, OH 43614, USA
    Carcinogenesis 28:124-9. 2007
    ..These results support the combined use of budesonide and R115777 in prevention of lung tumors and suggest that reversal of DNA hypomethylation in lung tumors would be useful as a surrogate end-point biomarker for prevention...
  28. ncbi Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone
    David L McCormick
    Life Sciences Group, IIT Research Institute Chicago, IL 60616, USA
    Carcinogenesis 28:398-403. 2007
    ..The chemopreventive activity of a non-androgenic DHEA analog suggests that at least a portion of the chemopreventive activity of DHEA in the rat prostate is unrelated to hormonal effects...
  29. ncbi Beta-ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-alpha in human colon cancer cells
    Naveena B Janakiram
    Department of Medicine, Hem Onc Section, OU Cancer Institute, University of Oklahoma Health Sciences Center, 975 Northeast 10th Street, BRC Building, Room 1203, Oklahoma City, OK 73104, USA
    Mol Cancer Ther 7:181-90. 2008
    ..0001) of foci containing four or more aberrant crypts. Results from in vitro and in vivo bioassay clearly suggest that beta-ionone could be further developed for prevention and treatment of colon cancer...
  30. ncbi Modulation by bexarotene of mRNA expression of genes in mouse lung tumors
    Fadel S Alyaqoub
    Department of Biochemistry and Cancer Biology, Medical University of Ohio, Toledo, Ohio, USA
    Mol Carcinog 47:165-71. 2008
    ....
  31. ncbi S-adenosyl L-methionine inhibits azoxymethane-induced colonic aberrant crypt foci in F344 rats and suppresses human colon cancer Caco-2 cell growth in 3D culture
    Suresh Guruswamy
    Department of Medicine, Hematology Oncology Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Int J Cancer 122:25-30. 2008
    ..0001). These observations demonstrate for the first time that SAM can reduce the occurrence of ACF in AOM treated male F344 rats and suppress formation of human tumor spheroids and expression of COX-2...
  32. ncbi Modulation by budesonide of DNA methylation and mRNA expression in mouse lung tumors
    Michael A Pereira
    Division of Hematology and Oncology, Ohio State University, College of Medicine, Columbus, OH 43210, USA
    Int J Cancer 120:1150-3. 2007
    ..Hence, budesonide rapidly decreased the size of lung tumors, reversed DNA hypomethylation and modulated mRNA expression of genes; with the molecular alterations requiring continued treatment with the drug for maintenance...
  33. ncbi Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor
    David L McCormick
    Life Sciences Group, IIT Research Institute, Chicago, Illinois 60616, USA
    Nutr Cancer 57:184-93. 2007
    ....
  34. ncbi Effect of budesonide on the methylation and mRNA expression of the insulin-like growth factor 2 and c-myc genes in mouse lung tumors
    Lianhui Tao
    Department of Pathology, Medical College of Ohio, Toledo, Ohio 43614, USA
    Mol Carcinog 35:93-102. 2002
    ..The results support the possibility of using decreased mRNA expression and remethylation of the Igf-II and c-myc genes as biomarkers for the efficacy of budesonide...
  35. ncbi Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites
    Anita L Sabichi
    Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:4606-13. 2003
    ..Thus, 4-MPR may play a role in the clinical activity of 4-HPR. This study further reveals the mechanism of action of these novel phenylretinamides and supports continued investigation into their development as chemopreventive drugs...
  36. ncbi AKT and the phosphatidylinositol 3-kinase/AKT pathway: important molecular targets for lung cancer prevention and treatment
    James A Crowell
    J Natl Cancer Inst 95:252-3. 2003
  37. ncbi Effects of body weight gain reduction resulting from chemopreventive agent treatment on mammary gland morphology
    Cristina Rodriguez-Burford
    Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Nutr Cancer 43:67-75. 2002
    ..It would appear that the observed decrease in mammary cancers observed with moderate reductions in body weight gain might be due to multiple related factors different from those related to 4-HPR treatment...
  38. ncbi Piroxicam selectively inhibits the growth of premalignant and malignant human oral cell lines by limiting their progression through the S phase and reducing the levels of cyclins and AP-1
    Haiming Ding
    Department of Radiology, The Ohio State University, Columbus, OH, USA
    Int J Cancer 107:830-6. 2003
    ....
  39. ncbi Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention
    Mark B Cope
    Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Oncol Rep 11:465-9. 2004
    ..In both experiments, the two retinoids in combination produced an additive effect, suggesting that they may inhibit mammary cancers by different mechanisms...
  40. ncbi Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer
    Lianhui Tao
    Department of Pathology, Medical College of Ohio, Toledo, Ohio, USA
    Mol Carcinog 39:79-84. 2004
    ..The results suggest that the ability to reverse the DNA hypomethylation in colon tumors could be useful as a surrogate end-point biomarker for chemoprevention of colon cancer...
  41. ncbi Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors
    Michael A Pereira
    Department of Pathology, Medical College of Ohio, Toledo, OH 43614, USA
    Carcinogenesis 25:1917-23. 2004
    ..Celecoxib and DFMO reversed DNA hypomethylation and the hypermethylation of the ER-alpha gene in colon tumors supporting the hypothesis that modulation of methylation is a biomarker of chemoprevention...
  42. ncbi Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents
    Lianhui Tao
    Department of Pathology, HEB, Rm 202, Medical College of Ohio, 3055 Arlington Ave, Toledo, OH 43614 5806, USA
    Carcinogenesis 23:1447-54. 2002
    ..Hence, agents that prevented colon cancer decreased the mitotic index and altered the expression of c-myc, p16 and p27 suggesting that modulation in the expression of these genes are potential biomarkers for chemopreventive activity...
  43. ncbi Low doses of beta-carotene and lutein inhibit AOM-induced rat colonic ACF formation but high doses augment ACF incidence
    Jayadev Raju
    Chemoprevention Program, Institute for Cancer Prevention, American Health Foundation Cancer Center, Valhalla, NY, USA
    Int J Cancer 113:798-802. 2005
    ..Taken together these data indicate that the chemopreventive activity of beta-carotene and lutein against colon carcinogenesis depends on the dose level...
  44. ncbi Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777
    William T Gunning
    Department of Pathology, Medical College of Ohio, Toledo 43614, USA
    Clin Cancer Res 9:1927-30. 2003
    ..The efficacy of R115777 [Zarnestra; (B)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)-methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone] to prevent the development of lung tumors in mice was determined...
  45. ncbi Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats
    Bandaru S Reddy
    Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, USA
    Cancer Res 66:4542-6. 2006
    ..These observations are of clinical significance because this can pave the way for the use of combinations of these agents in small doses against colon cancer...
  46. ncbi Prevention of mouse lung tumors by targretin
    Michael A Pereira
    Division of Hematology and Oncology, Ohio State University, College of Medicine, Columbus, OH 43210, USA
    Int J Cancer 118:2359-62. 2006
    ..75 and 4.60 +/- 0.70, respectively. Hence, targretin demonstrated both preventive and therapeutic activity with respect to mouse lung tumors supporting its further development as a preventive and therapeutic agent for lung cancer...
  47. ncbi Prevention of methylnitrosourea-induced mammary cancers by 9-cis-retinoic acid and/or vitamin D3
    Mark B Cope
    University of Alabama at Birmingham, Nutrition Sciences Department, Birmingham, AL 35294, USA
    Oncol Rep 9:533-7. 2002
    ..Possible interactions between the retinoic acid receptors and vitamin D receptor may be responsible for the observed inhibition of mammary carcinogenesis...
  48. ncbi Induction of apoptosis by 1,4-phenylenebis(methylene)selenocyanate in cultured human colon cancer cells
    Sang Kook Lee
    Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 60612, USA
    Anticancer Res 22:97-102. 2002
    ..Taken together, these results suggest that induction of apoptosis is one possible mechanism for the cancer chemopreventive activity mediated by p-XSC...
  49. ncbi Differential activity of NO synthase inhibitors as chemopreventive agents in a primary rat tracheal epithelial cell transformation system
    Sheela Sharma
    Cellular and Molecular Toxicology Program, ManTech Environmental Technology, Inc, Research Triangle Park, NC 27709, USA
    Neoplasia 4:332-6. 2002
    ..The data from this study identify NOS inhibitors as a novel class of chemopreventive agents that can be developed for lung cancer prevention...
  50. ncbi Prevention of mouse lung tumors by budesonide and its modulation of biomarkers
    Michael A Pereira
    Department of Pathology, Medical College of Ohio, HEB, Room 200F, 3055 Arlington Avenue, Toledo, OH 43614 5806, USA
    Carcinogenesis 23:1185-92. 2002
    ..Thus, short-term treatment with budesonide modulated biological and molecular end-points in lung tumors that might be developed further as biomarkers for its clinical chemopreventive efficacy in the lung...
  51. ncbi 9-cis-retinoic acid but not 4-(hydroxyphenyl)retinamide inhibits prostate intraepithelial neoplasia in Noble rats
    Konstantin T Christov
    Department of Surgical Oncology, College of Medicine, University of Illinois, 840 South Wood Street MC 820, Chicago, IL 60612, USA
    Cancer Res 62:5178-82. 2002
    ....
  52. ncbi Pharmacokinetic and pharmacodynamic study of NO-donating aspirin in F344 rats
    Chinthalapally V Rao
    Department of Medicine, Hematology Oncology Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    Int J Oncol 33:799-805. 2008
    ..These findings may have practical utility for the administration of NO-ASA to humans...
  53. ncbi Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice
    William T Gunning
    Department of Pathology, Medical College of Ohio, Toledo, Ohio 43614, USA
    Cancer Res 62:4199-201. 2002
    ..These results demonstrate that leukotriene inhibitors prevent lung tumors and slow the growth and progression of adenomas to carcinoma; leukotriene inhibitors warrant further consideration for potential use in humans...
  54. ncbi In situ detection of neoplastic transformation and chemopreventive effects in rat esophagus epithelium using angle-resolved low-coherence interferometry
    Adam Wax
    Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708, USA
    Cancer Res 63:3556-9. 2003
    ..This technique also may provide a new screening tool for intraepithelial neoplasia...
  55. ncbi Prospective grading of neoplastic change in rat esophagus epithelium using angle-resolved low-coherence interferometry
    Adam Wax
    Duke University, Department of Biomedical Engineering, Durham, North Carolina 27708, USA
    J Biomed Opt 10:051604. 2005
    ..We demonstrate that a/LCI is highly effective for monitoring neoplastic change and can be applied to assessing the efficacy of chemopreventive agents in the rat esophagus...
  56. ncbi Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice
    Malisetty V Swamy
    Department of Medicine, Hem Onc Section, University of Oklahoma Cancer Institute, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Cancer Res 66:7370-7. 2006
    ..These observations show that atorvastatin inhibits intestinal tumorigenesis and that, importantly, when given together with low doses of celecoxib, it significantly increases the chemopreventive efficacy in an APC(min) mice...
  57. ncbi Correlation of in vitro chemopreventive efficacy data from the human epidermal cell assay with animal efficacy data and clinical trial plasma levels
    Eugene Elmore
    Department of Radiation Oncology, University of California Irvine, Irvine, CA 92697, USA
    J Cell Biochem 95:571-88. 2005
    ..Thus, the HEC assay has an excellent predictive potential for animal efficacy and is responsive at clinically achievable concentrations...
  58. ncbi N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells
    Ann Marie Simeone
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 26:1000-7. 2005
    ..These in vitro results suggest that 4-HPR may be an effective chemopreventive agent against breast tumors that exhibit BRCA1 mutations because of its ability to induce NO-mediated apoptosis in such tumors...
  59. ncbi Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture
    Keith A Crist
    Department of Surgery, Medical College of Ohio, Toledo, OH 43614, USA
    Carcinogenesis 26:951-7. 2005
    ..Thus, the DMBA suture model in rats yields epithelial derived tumors histologically similar to humans and should prove suitable for the testing of preventive or therapeutic agents...
  60. ncbi Modulation by budesonide of a CpG endonuclease in mouse lung tumors
    Long Li
    Department of Biochemistry and Cancer Biology, Medical University of Ohio, 3055 Arlington Avenue, Toledo, OH 43614 5806, USA
    Carcinogenesis 28:1499-503. 2007
    ..The increased CpG endonuclease activity in mouse lung tumors and its inhibition by budesonide would suggest this endonuclease as a potential molecular target for chemoprevention...
  61. ncbi Potent carcinogenicity of cigarette smoke in mice exposed early in life
    Roumen Balansky
    Department of Health Sciences, University of Genoa, Via A Pastore 1, I 16132 Genoa, Italy
    Carcinogenesis 28:2236-43. 2007
    ..This animal model will be useful to explore the mechanisms involved in CS-induced carcinogenesis and to investigate the protective effects of dietary agents and chemopreventive drugs...
  62. ncbi The chemopreventive efficacy of inhaled oltipraz particulates in the B[a]P-induced A/J mouse lung adenoma model
    Sheela Sharma
    Cellular and Molecular Toxicology Program, Alion Life and Environmental Sciences, Research Triangle Park, NC 27709, USA
    Carcinogenesis 27:1721-7. 2006
    ..The data from this study show that oltipraz is an effective agent for lung cancer prevention, when it is delivered directly to the target tissue as aerosolized particulates...
  63. ncbi The human epithelial cell cytotoxicity assay for determining tissue specific toxicity: method modifications
    Eugene Elmore
    Department of Radiation Oncology and Chao Family Comprehensive Cancer Center, University of California, Medical Sciences I, B149, Irvine, CA 92697, USA
    Methods Cell Sci 24:145-53. 2002
    ....
  64. ncbi High susceptibility of neonatal mice to molecular, biochemical and cytogenetic alterations induced by environmental cigarette smoke and light
    Silvio De Flora
    Department of Health Sciences, University of Genoa, Via A Pastore 1, I 16132 Genoa, Italy
    Mutat Res 659:137-46. 2008
    ..The findings of these studies provide a mechanistic clue to the general concept that the neonatal period and early stages of life are critical in affecting susceptibility to carcinogens...
  65. ncbi Preneoplastic and neoplastic lesions in the lung, liver and urinary tract of mice exposed to environmental cigarette smoke and UV light since birth
    Francesco D'Agostini
    Department of Health Sciences, University of Genoa, Genoa, Italy
    Int J Cancer 123:2497-502. 2008
    ..The results obtained with ECS cannot be directly compared to those previously obtained with MCS, since the latter involved shorter daily exposures to more massive CS doses...